Trials / Completed
CompletedNCT00329095
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Robin, Alan L., M.D. · Individual
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
Detailed description
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | travoprost, latanoprost, or bimatoprost | |
| DRUG | Additional ocular hypotensive medication |
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-04-01
- First posted
- 2006-05-24
- Last updated
- 2006-05-24
Source: ClinicalTrials.gov record NCT00329095. Inclusion in this directory is not an endorsement.